Placebo-controlled Trial of Nimodipine in the Treatment of Acute Ischemic Cerebral Infarction.


Phase N/A Results


Mortality rates did not differ significantly between groups. Neurologic outcome after 28 days of therapy did not differ between groups. However, when only those patients most likely to benefit from any intervention (Mathew Scale sum score <= 65 at baseline) were analyzed separately in post hoc-defined subgroups, the nimodipine-treated subgroups showed a significantly better neurologic outcome.